|
|
Prepublished online as a Blood First Edition Paper on December 27, 2002; DOI 10.1182/blood-2002-09-2908.
Submitted September 24, 2002
Accepted December 17, 2002
The serine protease granzyme M is preferentially expressed in NK-cell,   T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity
Laszlo Krenacs, Mark J Smyth, Eniko Bagdi, Tibor Krenacs, Laszlo Kopper, Thomas Rudiger, Andreas Zetti, Hans Konrad Mueller-Hermelink, Elaine S Jaffe, and Mark Raffeld*
Laboratory of Tumor Pathology and Molecular Diagnostics, Institute of Biotechnology, Bay Zoltan Foundation for Applied Research, Szeged, Hungary
Division of Cancer Immunology, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia
1st Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Budapest, Hungary
Department of Pathology, University of Wurzburg,, Wurzburg, Germany
Specialized Diagnostics Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Hematopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
* Corresponding author; email: mraff{at}box-m.nih.gov.
Granzyme M (GM) is a novel serine protease whose expression is highly restricted to natural killer cells, CD3+ CD56+ T-cells, and   T-cells. Using a GM-specific monoclonal antibody, we analyzed its expression in 215 mature T-cell and NK-cell lymphomas. GM was preferentially expressed in nasal NK/T-cell lymphomas (100%), T-cell lymphomas (100%), and intestinal T-cell lymphomas (85%). In contrast, GM expression was present at low prevalence in mycosis fungoides/Sezary syndrome (3%), anaplastic large cell lymphoma (6%), panniculitis-like T-cell lymphoma (11%), and angioimmunoblastic T-cell lymphoma (0%) cases. Peripheral T-cell lymphomas of unspecified subtype showed an intermediate frequency (37%) of GM expression, consistent with their heterogeneous origin. We conclude that GM expression is a distinctive feature of the nasal NK/T-cell, T-cell and intestinal T-cell lymphomas, and suggests that these tumors develop from lymphocytes involved in innate immunity.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Wu, L. Wang, G. Hua, K. Liu, X. Yang, Y. Zhai, M. Bartlam, F. Sun, and Z. Fan
Structural Basis for Proteolytic Specificity of the Human Apoptosis-Inducing Granzyme M
J. Immunol.,
July 1, 2009;
183(1):
421 - 429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al.
Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
Blood,
March 1, 2007;
109(5):
2183 - 2189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Waterhouse, V. R. Sutton, K. A Sedelies, A. Ciccone, M. Jenkins, S. J. Turner, P. I. Bird, and J. A. Trapani
Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis.
J. Cell Biol.,
April 10, 2006;
173(1):
133 - 144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Jaffe
Pathobiology of Peripheral T-cell Lymphomas
Hematology,
January 1, 2006;
2006(1):
317 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bade, H. E. Boettcher, J. Lohrmann, C. Hink-Schauer, K. Bratke, D. E. Jenne, J. C. Virchow Jr, and W. Luttmann
Differential expression of the granzymes A, K and M and perforin in human peripheral blood lymphocytes
Int. Immunol.,
November 1, 2005;
17(11):
1419 - 1428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
